Home Compare MRNA vs ROIV
Stock Comparison · Industry comparison · Biotechnology

Moderna vs Roivant Sciences: Which Stock Looks Stronger in 2026?

Roivant Sciences leads structurally, with stability as the clearest single gap between the two profiles. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the separation is still concentrated in stability. The overall score gap is 12 points in favour of Roivant Sciences Ltd..

INDUSTRY COMPARISON

Both operate in: Biotechnology

This comparison is based on industry proximity, not on functional trajectory similarity. MRNA and ROIV share the same industry classification.

For a similarity-based comparison, see how Moderna and Roivant Sciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
MRNA
Moderna, Inc.
16
Peer-Score
Signal qualityHigh
vs
ROIV
Roivant Sciences Ltd.
28
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in stability.

Dimension spread: MRNA vs ROIV Profitability 15 Stability 3 53 Valuation 30 30 Growth 9 0 MRNA ROIV
Gap Ranking
#1 Stability +50
#2 Growth +9
#3 Valuation
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for MRNA and ROIV Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer MRNAROIV Relative valuation Structural strength

The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.

Valuation position uses peer-relative valuation score where available.

Relative Position vs Comparable Companies
Stability
On stability, Roivant Sciences Ltd. is positioned higher in the group, while Moderna, Inc. is closer to the middle.
Growth
Neither side looks especially strong on growth, though Moderna, Inc. still ranks somewhat higher.
Stability — Dominant Gap
MRNA
3
ROIV
53
Gap+50in favour of ROIV

The clearest distance comes from a steadier profile over time.

What keeps the gap from being one-sided

Moderna still pushes back on growth, with a 48-point revenue-growth advantage that keeps the read from becoming one-way.

What this means for the comparison

Stability clearly separates the pair, while the broader read stays strong rather than one-way.

Explore full peer positioning in AssetNext

Break down the MRNA vs ROIV comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar stability-driven comparisons

Explore how MRNA and ROIV each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.